160 related articles for article (PubMed ID: 35116602)
1. Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A).
Wang L; Wang X; Ren X; Han C; Xiao Z; Zhu S; Qiao X; Zhou Z; Shen W; Chen J; Pang Q; Zhang W; Zhao Y; Wang X; Sun X; Ge X; Zhang K; Hu M; Li G; Liu M; Wang Y
Transl Cancer Res; 2021 Jun; 10(6):2932-2943. PubMed ID: 35116602
[TBL] [Abstract][Full Text] [Related]
2. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
[TBL] [Abstract][Full Text] [Related]
4. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
Liu A; Wang Y; Wang X; Zhu L; Nie Y; Li M
Radiat Oncol; 2021 Oct; 16(1):195. PubMed ID: 34600574
[TBL] [Abstract][Full Text] [Related]
5. Survival Comparision of Three-dimensional Radiotherapy Alone vs. Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.
Zhang AD; Su XH; Shi GF; Han C; Wang L; Liu H; Zhang J; Zhang RH
Arch Med Res; 2020 Jul; 51(5):419-428. PubMed ID: 32418649
[TBL] [Abstract][Full Text] [Related]
6. Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A).
Chen M; Liu X; Han C; Wang X; Zhao Y; Pang Q; Sun X; Li G; Zhang K; Li L; Qiao X; Lin Y; Chen J; Xiao Z
BMC Cancer; 2020 Jan; 20(1):36. PubMed ID: 31941487
[TBL] [Abstract][Full Text] [Related]
7. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].
Wang XM; Wang L; Wang X; Chen JQ; Li C; Zhang WC; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Han C; Pang QS; Wang P; Sun XC; Zhang KX; Li GF; Li L; Liu ML; Wang YD; Qiao XY; Zhu SC; Zhou ZM; Zhao YD; Xiao ZF
Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):889-896. PubMed ID: 34407597
[No Abstract] [Full Text] [Related]
8. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Outcomes of Locally Advanced Cervical Esophageal Squamous Cell Carcinoma Patients Receiving Curative Concurrent Chemoradiotherapy: A Population-Based Propensity Score-Matched Analysis.
Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Li SH
Cancers (Basel); 2019 Mar; 11(4):. PubMed ID: 30934987
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
Song T; Du D; Zhang X; Fang M; Wu S
Dis Esophagus; 2017 Sep; 30(9):1-10. PubMed ID: 28859362
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of Hematoxylin and eosin staining tumor-infiltrating lymphocytes (H&E-TILs) in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy.
Zheng J; Zhang H; Li S; Kang Z; Zheng F; Yao Q; Zhang X; Wu Z; Wang J; Fang W; Li J; Chen G; Chen Y; Chen M
BMC Cancer; 2023 Dec; 23(1):1193. PubMed ID: 38053017
[TBL] [Abstract][Full Text] [Related]
13. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey.
Li C; Wang X; Wang L; Chen J; Zhang W; Pang Q; Zhao Y; Sun X; Zhang K; Li G; Li L; Qiao X; Liu M; Wang Y; Deng L; Wang W; Bi N; Zhang T; Deng W; Ni W; Chang X; Han W; Zhou Z; Liang J; Feng Q; Wang L; Chen D; Lv J; Zhu S; Han C; Xiao Z
Acta Oncol; 2021 May; 60(5):627-634. PubMed ID: 33793382
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
Shi Z; Zhu X; Ruan C; Wei G; Li J; Qiu H; Gao L; Cai G; Zhangcai Y; Li B; Wang J; Gong Y; Chen J; Zhao W; Wu Y; Ke S; Chen Y
JAMA Netw Open; 2022 Dec; 5(12):e2244619. PubMed ID: 36454568
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
16. Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis.
Wang J; Xiao L; Wang S; Pang Q; Wang J
Front Oncol; 2021; 11():665231. PubMed ID: 34589418
[TBL] [Abstract][Full Text] [Related]
17. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.
Shi Z; Zhu X; Ke S; Qiu H; Cai G; Zhangcai Y; Chen Y
Radiother Oncol; 2021 Nov; 164():236-244. PubMed ID: 34627936
[TBL] [Abstract][Full Text] [Related]
18. Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?
Zhang P; Xi M; Zhao L; Shen JX; Li QQ; He LR; Liu SL; Liu MZ
PLoS One; 2014; 9(8):e105270. PubMed ID: 25133495
[TBL] [Abstract][Full Text] [Related]
19. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC.
Wang G; Beeraka NM; Xiao W; Zhang Y; Xue N; Chen G; Liu J; Liu Y
Technol Cancer Res Treat; 2022; 21():15330338221080939. PubMed ID: 35235470
[No Abstract] [Full Text] [Related]
20. A retrospective study of postoperative radiotherapy for locally advanced esophageal squamous cell carcinoma.
Zhang Z; Xu L; Di X; Zhang C; Ge X; Sun X
Ann Palliat Med; 2019 Nov; 8(5):708-716. PubMed ID: 31865731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
